High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide

被引：0
|
作者：
Maryam Pourabdollah
Mohammad Bahmanyar
Eshetu G. Atenafu
Donna Reece
Jian Hou
Hong Chang
机构：
[1] University of Toronto,Department of Laboratory Medicine and Pathobiology
[2] University of Toronto,Department of Biostatistics
[3] University of Toronto,Department of Hematology and Medical Oncology
[4] Shanghai Chang Zheng Hospital,Department of Hematology
[5] University Health Network,Department of Laboratory Hematology
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
Multiple Myeloma; Myeloma; Myeloma Cell; Lenalidomide; Myeloma Patient;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The aim of this study is to assess nucleoprotein expression of IKZF1/3 in patients with relapsed/refractory multiple myeloma (MM) who received lenalidomide-based therapy and correlated them with their clinical outcomes. A total of 50 patients diagnosed with MM were entered in the study with the median follow-up of 86.4 months. By immunohistochemistry (IHC), IKZF1 and IKZF3 were expressed in 72 and 58% of the cases, respectively. IKZF1 and IKZF3 expressions were associated with longer median progression free survival (P = 0.0029 and P < 0.0001) and overall survival (P = 0.0014 and P < 0.0001). IKZF3 expression also appears predicted a favorable response to the lenalidomide-based therapy.
引用
收藏
相关论文
共 50 条
  • [1] High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
    Pourabdollah, Maryam
    Bahmanyar, Mohammad
    Atenafu, Eshetu G.
    Reece, Donna
    Hou, Jian
    Chang, Hong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide
    Pourabdollah, Maryam
    Bahmanyar, Mohammad
    Atenafu, Eshetu G.
    Reece, Donna
    Chang, Hong
    BLOOD, 2016, 128 (22)
  • [3] LOW IKZF1 EXPRESSION IS ASSOCIATED WITH FAVORABLE OUTCOME IN LENALIDOMIDE TREATED NEWLY DIAGNOSED MULTIPLE MYELOMA
    Kroenke, J.
    Kuchenbauer, F.
    Kull, M.
    Teleanu, V.
    Bullinger, L.
    Greiner, A.
    Kolmus, S.
    Koepff, S.
    Muegge, L. O.
    Straka, C.
    Bassermann, F.
    Engelhardt, M.
    Bargou, R.
    Einsele, H.
    Knop, S.
    Langer, C.
    HAEMATOLOGICA, 2015, 100 : 311 - 312
  • [4] IKZF1 expression is associated with outcome in lenalidomide treated newly diagnosed multiple myeloma
    Kuchenbauer, E.
    Kroenke, J.
    Kull, M.
    Teleanu, V
    Bullinger, L.
    Straka, C.
    Muegge, L-O
    Bassermann, F.
    Engelhardt, M.
    Bargou, R.
    Einsele, H.
    Knop, S.
    Langer, C.
    Oncology Research and Treatment, 2015, 38 : 10 - 10
  • [5] The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma
    Awwad, Mohamed H. S.
    Kriegsmann, Katharina
    Plaumann, Julian
    Benn, Michael
    Hillengass, Jens
    Raab, Marc S.
    Bertsch, Uta
    Munder, Markus
    Weisel, Katja
    Salwender, Hans Juergen
    Haenel, Mathias
    Fenk, Roland
    Duerig, Jan
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Hundemer, Michael
    ONCOIMMUNOLOGY, 2018, 7 (10):
  • [6] The Prognostic and Predictive Value of IKZF1 and IKZF3 Expression in T-Cells in Patients with Multiple Myeloma
    Awwad, Mohamed H. S.
    Kriegsmann, Katharina
    Plaumann, Julian
    Benn, Michael
    Hillengass, Jens
    Raab, Marc-Steffen S.
    Bertsch, Uta
    Munder, Markus
    Weisel, Katja C.
    Salwender, Hans Jurgen
    Hanel, Mathias
    Fenk, Roland
    Durig, Jan
    Mueller-Tidow, Carsten
    Goldschmidt, Hartmut
    Hundemer, Michael
    BLOOD, 2017, 130
  • [7] Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
    Kroenke, Jan
    Udeshi, Namrata D.
    Narla, Anupama
    Grauman, Peter
    Hurst, Slater N.
    McConkey, Marie
    Svinkina, Tanya
    Heckl, Dirk
    Comer, Eamon
    Li, Xiaoyu
    Ciarlo, Christie
    Hartman, Emily
    Munshi, Nikhil
    Schenone, Monica
    Schreiber, Stuart L.
    Carr, Steven A.
    Ebert, Benjamin L.
    SCIENCE, 2014, 343 (6168) : 301 - 305
  • [8] Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Stadtmauer, Edward A.
    Rajkumar, S. Vincent
    Siegel, David
    Bravo, Marie-Laure
    Olesnyckyj, Marta
    Knight, Robert D.
    Zeldis, Jerome B.
    Harousseau, Jean-Luc
    Weber, Donna M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (01): : 38 - 43
  • [9] Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide
    Abdulkarim, Haya
    Zourob, Mohammed
    Siaj, Mohamed
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [10] Development of Label-Free Impedimetric Immunosensors for IKZF1 and IKZF3 Femtomolar Detection for Monitoring Multiple Myeloma Patients Treated with Lenalidomide
    Haya Abdulkarim
    Mohammed Zourob
    Mohamed Siaj
    Scientific Reports, 10
12345